BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 17408402)

  • 1. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
    Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A
    Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML.
    Litzow MR; Dietz AB; Bulur PA; Butler GW; Gastineau DA; Hoering A; Fink SR; Letendre L; Padley DJ; Paternoster SF; Tefferi A; Vuk-Pavlović S
    Cytotherapy; 2006; 8(3):290-8. PubMed ID: 16793737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
    Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
    Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia.
    Westermann J; Schlimper C; Richter G; Mohm J; Dörken B; Pezzutto A
    Br J Haematol; 2004 Apr; 125(2):213-6. PubMed ID: 15059144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
    Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
    Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum-free culture of dendritic cells from patients with chronic myeloid leukemia in vitro and estimation of their cytotoxicity.
    Zhao W; Xing P; Wei X; Wang T; Yang D; Li M
    Chin Med J (Engl); 2002 Sep; 115(9):1296-300. PubMed ID: 12411098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
    Boissel N; Rousselot P; Raffoux E; Cayuela JM; Soulier J; Mooney N; Charron D; Dombret H; Toubert A; Rea D
    J Leukoc Biol; 2006 Apr; 79(4):747-56. PubMed ID: 16461746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
    Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
    Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
    Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
    Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation.
    Orsini E; Calabrese E; Maggio R; Pasquale A; Nanni M; Trasarti S; Tafuri A; Guarini A; Foa R
    Leuk Res; 2006 Jul; 30(7):785-94. PubMed ID: 16527350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells.
    Rapoport AP; Levine BL; Badros A; Meisenberg B; Ruehle K; Nandi A; Rollins S; Natt S; Ratterree B; Westphal S; Mann D; June CH
    Bone Marrow Transplant; 2004 Jan; 33(1):53-60. PubMed ID: 14578928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of ST1571 on the development of dendritic cells derived from bone marrow mononuclear cells in patients with chronic myeloid leukemia].
    Zheng SE; Jin J; Tong XM; Qian WB; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):920-3. PubMed ID: 17533744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.
    Li Z; Qiao Y; Liu B; Laska EJ; Chakravarthi P; Kulko JM; Bona RD; Fang M; Hegde U; Moyo V; Tannenbaum SH; Ménoret A; Gaffney J; Glynn L; Runowicz CD; Srivastava PK
    Clin Cancer Res; 2005 Jun; 11(12):4460-8. PubMed ID: 15958631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells.
    Smit WM; Rijnbeek M; van Bergen CA; de Paus RA; Vervenne HA; van de Keur M; Willemze R; Falkenburg JH
    Hum Immunol; 1997 Apr; 53(2):216-23. PubMed ID: 9129981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helper and cytotoxic lymphocyte responses to chronic myeloid leukaemia: implications for adoptive immunotherapy with T cells.
    Lewalle P; Hensel N; Guimaraes A; Couriel D; Jiang Y Z; Mavroudis D; Barrett AJ
    Br J Haematol; 1996 Mar; 92(3):587-94. PubMed ID: 8616022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schmid C; Schweiger C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):75-85. PubMed ID: 16091127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.